Kevin Accola, MD, spoke to Cardiovascular Business about new 10-year data on the performance of surgical valves featuring Resilia tissue. The findings are good news for Edwards Lifesciences, which also includes the tissue on many of its TAVR devices.
Becoming a father seems to make a man less likely to die young. What’s more, when a father passes away within the first five years of his child’s life, the cause is usually non-natural and thus preventable.
Treating AFib with surgical ablation during mitral valve surgery and other common heart operations can help patients live longer, a new meta-analysis confirmed.
Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.
Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.
Palliative care is a recommended part of heart failure management in the U.S., but consultation rates remain low. The trend appears to impact Black patients more than other races and ethnicities.
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.
